MC2R — the ACTH receptor

Here the same family that colours skin reaches all the way to the adrenal — one signal, stretched from the body's surface to the chemistry of stress.

Tissue

Adrenal cortex

Key ligands

ACTH only (uniquely selective)

Signalling

Gs → cAMP → PKA, driving adrenal steroidogenesis

Accessory protein

MRAP — required to reach the cell surface

Gene

18p11.21

Function

The ACTH receptor — drives adrenal steroidogenesis and cortisol output at the bottom of the HPA stress axis.

When it fails

Mutations cause familial glucocorticoid deficiency; the receptor needs the accessory protein MRAP to reach the cell surface.

MC2R is the odd one out of the melanocortin family. Where the other four receptors respond to several melanocortin peptides, MC2R answers to just one — ACTH — and it sits in just one main place: the cortex of the adrenal gland, where it forms the final step of the body's stress-hormone axis.^[1]It is also the only one of the five that is not a complete machine on its own. What follows is the story of a receptor that needs a partner, reads a password, and was the first in the family to explain a human disease.

The end of the stress axis

Stress and circadian cues drive the hypothalamus to release CRH, which makes the pituitary secrete ACTH, which travels in the blood to the adrenal cortex and binds MC2R. Like its relatives, MC2R couples to Gs and raises cyclic AMP; through protein kinase A this switches on the steroidogenic machinery that produces cortisol (and contributes to adrenal androgens).^[2] This hypothalamic–pituitary–adrenal (HPA) loop is the circuit that the overview pillar describes ACTH serving — and MC2R is its receiving end. The receptor is expressed in all three zones of the adrenal cortex, most densely in the cortisol-producing zona fasciculata, and ACTH acting through it is trophic as well as acute: chronic ACTH excess makes the cortex grow, and ACTH deficiency makes it shrink.^[1]

The MC2R gene

MC2R was cloned in 1992 alongside MC1R, in the paper that founded the melanocortin receptor family. The screen was designed to find the receptor for MSH in melanoma cells; the second gene it pulled out was expressed instead in the adrenal cortex and encoded the long-sought ACTH receptor.^[4] It is the smallest G-protein-coupled receptor in the family — 297 amino acids, against 332 for MC4R — and, like all five, it is encoded by a single intronless exon. The gene sits on the short arm of chromosome 18, at 18p11.21, immediately adjacent to MC5R; the two are thought to have arisen by a local duplication.^[2] It was also the first melanocortin receptor to be tied to a human disease. Within a year of its cloning, a point mutation in MC2R was found in a family with inherited adrenal failure, which made the ACTH receptor one of the earliest GPCRs linked to a Mendelian disorder.^[5]

Why only ACTH?

The melanocortins share a common His-Phe-Arg-Trp core, which is enough to activate MC1R and MC3R–MC5R. MC2R is different: it additionally requires a stretch of ACTH present only in the full hormone and not in the shorter MSH peptides.^[1] The idea goes back to Robert Schwyzer, who proposed in the 1970s that ACTH carries two kinds of information: a “message” — the His-Phe-Arg-Trp motif at positions 6–9 that is common to the whole family — and an “address”, the run of basic residues Lys-Lys-Arg-Arg-Pro at positions 15–19 that the adrenal receptor demands.^[9] α-MSH is ACTH(1–13): it has the message but stops before the address, and so cannot meaningfully switch MC2R on. Mutagenesis and chimera studies have since located the receptor residues that read the address and shown how MRAP1 helps present them, though the picture is still being refined.^[10] The practical consequence is a built-in guard: a system that uses the same core peptide to colour skin, curb appetite and resolve inflammation can do all of that without accidentally triggering cortisol. It also sets the minimum size of any MC2R agonist. The shortest ACTH fragment with full adrenal activity is ACTH(1–24), which is exactly what the clinical test compound is.

It needs a chaperone: MRAP

On its own, MC2R cannot reach the cell surface. For years this made it almost impossible to study, because the receptor refused to work in any cell line that was not adrenal. The explanation came in 2005 from human genetics. In families with inherited adrenal failure but no MC2R mutation, the culprit turned out to be a previously unnamed gene encoding a small single-pass membrane protein — the melanocortin-2-receptor accessory protein, MRAP — that interacts with MC2R and is required for it to leave the endoplasmic reticulum and respond to ACTH.^[6] Expressing MRAP alongside MC2R finally let the receptor function in ordinary cells, and reframed MC2R as a two-component system: receptor plus escort.

MRAP is odd in its own right. It inserts into the membrane in both orientations and pairs up as an antiparallel homodimer — one copy with its amino-terminus outside the cell, the other with it inside — a topology that had no precedent among membrane proteins.^[7] The amino-terminal region, which carries a short motif essential for ACTH binding, therefore appears on both sides of the membrane at once. Its paralogue MRAP2 can also carry MC2R to the surface but, unlike MRAP1, does not support a normal ACTH response; in the lab it competes with MRAP1 and dampens MC2R signalling. Both proteins also interact with the other four melanocortin receptors, where MRAP1 and MRAP2 tend to reduce surface expression and signalling.^[8] That is the origin of a distinction this site keeps stressing: MRAP1 is MC2R's indispensable partner; MRAP2 is a modulator, best known for tuning MC4R and MC3R, and its variants are linked to obesity rather than to adrenal disease.

The receptor in three dimensions

MC2R was among the last of the five to be seen, and it could not be seen alone. The 2023 cryo-EM structure captured the human receptor in complex with MRAP1, bound to ACTH and coupled to Gs.^[11] The chaperone wraps across the receptor's transmembrane bundle and extracellular face, and the structure explains both of MC2R's peculiarities at once. MRAP1 stabilises the receptor fold, which is why MC2R cannot traffic without it, and it reshapes the entrance to the binding pocket so that a hormone far larger than the His-Phe-Arg-Trp core can be read — including the basic address that no MSH peptide carries.^[11] The core itself sits in the family's shared calcium-assisted pocket, which is why drugs aimed at MC4R or MC1R can brush MC2R, and why selectivity is the melanocortin field's recurring problem. The structural biology page tells that story for the whole family.

When it fails: familial glucocorticoid deficiency

Loss-of-function mutations in MC2R cause familial glucocorticoid deficiency (FGD) type 1, an autosomal recessive condition in which the adrenal cortex cannot mount a normal cortisol response to ACTH. Children present in infancy or early childhood with hypoglycaemia, seizures, recurrent infection, failure to thrive, and often deep skin pigmentation — because the pituitary, sensing no cortisol, pours out ACTH, and the excess spills over onto the pigment receptor MC1R. Mineralocorticoid production is characteristically preserved, since aldosterone answers mainly to the renin–angiotensin system rather than to ACTH.^[2] When the disease-causing mutations were examined one by one, most turned out to work not by abolishing signalling but by stranding the receptor inside the cell — even when MRAP was present — a trafficking failure rather than a signalling one.^[3] MRAP mutations cause the clinically similar FGD type 2, which tends to present even earlier; together the two genes account for roughly half of FGD, and the remainder has since been traced to genes for oxidative-stress defence and DNA repair in the adrenal.^[2] It is a reminder that, here, the chaperone is as load-bearing as the receptor.

Beyond the adrenal

MC2R is close to adrenal-specific in humans, but not perfectly so. In rodents it is clearly expressed in fat, where ACTH is a potent lipolytic hormone, and MC2R messenger RNA is found in both white and brown adipose depots and rises sharply as fat cells differentiate.^[13] That makes ACTH a direct mobiliser of stored energy during stress in mice — a peripheral melanocortin effect to set beside the fuel-handling role of MC5R. In humans the adipose expression is low and the lipolytic effect of ACTH modest, and the receptor has also been reported at low levels in skin.^[2] The clinically important lesson runs the other way: because MC2R is so nearly confined to the adrenal, a drug that hits it will have, in effect, one organ-level consequence, and that consequence is cortisol.

Why it matters clinically

MC2R is the molecular target of the standard test of adrenal reserve. The short Synacthen or cosyntropin test gives a dose of synthetic ACTH(1–24) — tetracosactide — and measures whether the adrenal cortex, through MC2R, answers with a rise in cortisol; a blunted response is the recommended confirmatory test for primary adrenal insufficiency.^[12] The same peptide, as a depot preparation, is used therapeutically in a handful of conditions, which the therapeutics page covers. The axis also explains a classic clinical sign: disorders that drive ACTH very high, from Addison's disease to FGD, darken the skin because the excess ACTH reaches MC1R. It is the melanocortin system quietly showing its unity — one family, read in two very different tissues.

Blocking the ACTH receptor

The newest chapter is the attempt to turn MC2R off. Several conditions are driven by too much ACTH signalling at the adrenal: congenital adrenal hyperplasia, where a cortisol-synthesis block sends ACTH soaring and the excess drives adrenal androgen overproduction; and ACTH-dependent Cushing's syndrome, from pituitary or ectopic tumours that secrete the hormone. A selective MC2R antagonist would cut the adrenal response at its receptor whatever the source of the ACTH, and oral non-peptide antagonists have now reached mid-stage clinical trials in both conditions. In a 12-week phase 2 study in adults with classic congenital adrenal hyperplasia, the first of them, atumelnant, cut the androgen precursor androstenedione by well over half within days and held it there, on top of unchanged glucocorticoid replacement.^[14] None has yet been approved, and the obvious design constraint is that the brake must be adjustable: a patient still needs cortisol, so an antagonist has to be dosed, or paired with replacement, rather than simply switched on. For the state of play across the family, see the pipeline.

Pharmacologically MC2R is the cleanest target in the family, because its strict ligand requirement means an antagonist built around the ACTH address need not touch the four receptors that read only the message. The problem the other receptors face — the shared pocket that makes a clean MC1R drug so hard — is, at MC2R, solved by the biology itself.

For how MC2R fits the broader system, see the overview pillar; its only ligand has its own page at ACTH.

← Back to all receptors